Sign In
Buy BBIO
$65.48
+1.60 (+2.50%)
At Close: Jun 03, 2026
Tracking Ole Andreas Halvorsen's Viking Global Portfolio - Q2 2020 Update
10:49am, Friday, 11'th Sep 2020
Halvorsen's 13F portfolio value increased from $19.21B to $23.14B. The number of positions increased from 64 to 71.
BridgeBio Pharma (NASDAQ:BBIO) Given Average Rating of “Hold” by Brokerages
04:10am, Tuesday, 25'th Aug 2020
Shares of BridgeBio Pharma (NASDAQ:BBIO) have received an average rating of “Hold” from the twelve analysts that are covering the company, Marketbeat reports. Two investment analysts have rated th
Late-stage biotech ETFs rally Monday on virus treatment hopes
04:37pm, Monday, 17'th Aug 2020
Late-stage biotech exchange-traded funds were among the day's biggest gainers Monday as investors pinned their hopes on medical responses to the novel...
Week In Review: $2.5 Billion In Deals Including LianBio's Initial $719 Million In In-Licensings
08:13am, Sunday, 16'th Aug 2020
LianBio, a new Princeton-Shanghai company founded by Perceptive Advisors, acquired China rights to two BridgeBio oncology assets in a $531.5 million agreement.
BridgeBio Pharma Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
08:30pm, Wednesday, 12'th Aug 2020
PALO ALTO, Calif., Aug. 12, 2020 (GLOBE NEWSWIRE) -- BridgeBio Pharma, Inc. (Nasdaq: BBIO), a clinical-stage biopharmaceutical company focused on genetic diseases, today announced that on August 3, 20
BridgeBio Pharma, Inc. Reports Second Quarter 2020 Financial Results and Business Update
11:40am, Tuesday, 11'th Aug 2020
-Initiated four clinical trials, progressed its additional 11 ongoing clinical trials and submitted three INDs to FDA since the beginning of 2020 -Strategic collaboration with Perceptive Advisors-fou
$26.5 million total near-term payments to BridgeBio, plus participation in long-term value creation of up to $505 million in milestone payments, tiered double-digit royalty payments and an equity inte
Perceptive Advisors Launches LianBio with Multiple Strategic Alliances and Establishes Operating Platform
12:00am, Tuesday, 11'th Aug 2020
Perceptive Advisors launches LianBio with multiple strategic alliances to develop and commercialize therapeutics in China and major Asian markets.
* Precision medicine study designed to confirm drug’s ability to cross blood-brain barrier and hit molecular targets in high-grade glioma patients with FGFR genetic alterations * Patients with a po
Heron's Cinvanti Progress, And Other News: The Good, Bad And Ugly Of Biopharma
10:46pm, Thursday, 16'th Jul 2020
Heron Therapeutics advances Phase 2 Study of CINVANTI. BridgeBio Pharma starts dosing in Phase 2 clinical trial.
Wells Fargo & Company MN Has $1.11 Million Holdings in BridgeBio Pharma (NASDAQ:BBIO)
04:30pm, Thursday, 16'th Jul 2020
Wells Fargo & Company MN grew its holdings in shares of BridgeBio Pharma (NASDAQ:BBIO) by 174.6% during the first quarter, according to the company in its most recent filing with the Securities & Exch
SAN FRANCISCO, July 15, 2020 -- BridgeBio Pharma, Inc. (Nasdaq: BBIO) affiliate QED Therapeutics announced today that the first child with achondroplasia has been dosed with.
BOSTON, July 10, 2020 -- BridgeBio Pharma, Inc. (Nasdaq: BBIO) affiliate Phoenix Tissue Repair (PTR) today announced an upcoming presentation of interim data from an ongoing.
BridgeBio Pharma Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
08:30pm, Monday, 06'th Jul 2020
PALO ALTO, Calif., July 06, 2020 -- BridgeBio Pharma, Inc. (Nasdaq: BBIO), a clinical-stage biopharmaceutical company focused on genetic diseases, today announced that on July.
